

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:03:26 ON 30 DEC 2003

=> file medline caplus embase biotechno scisearch biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 13:04:08 ON 30 DEC 2003

FILE 'CAPLUS' ENTERED AT 13:04:08 ON 30 DEC 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:04:08 ON 30 DEC 2003  
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 13:04:08 ON 30 DEC 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:04:08 ON 30 DEC 2003  
COPYRIGHT 2003 THOMSON ISI

FILE 'BIOSIS' ENTERED AT 13:04:08 ON 30 DEC 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s clcal  
L1 104 CLCAL

=> s hclcal  
L2 75 HCLCAL

=> s clca-1  
L3 14 CLCA-1

=> hclca-1  
HCLCA-1 IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s hclca-1  
L4 10 HCLCA-1

=> s l1 or l2 or l3 or l4  
L5 175 L1 OR L2 OR L3 OR L4

=> s l5 and ribozyme  
L6 1 L5 AND RIBOZYME

=> s l5 and antisense  
L7 12 L5 AND ANTISENSE

=> s l5 and sirna  
L8 0 L5 AND SIRNA

=> s l5 and rnai  
L9 0 L5 AND RNAI

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1805SXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPlus records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	DEC 08	INPADOC: Legal Status data reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added
NEWS	14	OCT 21	BIOSIS file reloaded and enhanced
NEWS	15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	16	NOV 24	MSDS-CCOHS file reloaded
NEWS	17	DEC 08	CABA reloaded with left truncation
NEWS	18	DEC 08	IMS file names changed
NEWS	19	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	20	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPlus
NEWS	21	DEC 17	DGENE: Two new display fields added
NEWS	22	DEC 18	BIOTECHNO no longer updated
NEWS	23	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	24	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	25	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	26	DEC 22	ABI-INFORM now available on STN
NEWS EXPRESS	DECEMBER 28	CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003	
NEWS HOURS		STN Operating Hours Plus Help Desk Availability	
NEWS INTER		General Internet Information	
NEWS LOGIN		Welcome Banner and News Items	
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN	
NEWS WWW		CAS World Wide Web Site (general information)	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

=> s dup rem l7  
MISSING OPERATOR REM L7  
The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> dup rem l7  
PROCESSING COMPLETED FOR L7  
L10 7 DUP REM L7 (5 DUPLICATES REMOVED)

=> d ab 1-7

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AB It is intended to provide diagnostics and therapeutics for bronchial asthma or chronic obstructive pulmonary disease. Namely, diagnostics, etc. for respiratory diseases characterized by contg.: (1) an antibody against a protein having an amino acid sequence which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO:1; (2) an antibody against a protein having an amino acid sequence which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO:2; and (3) an antibody against a protein having an amino acid sequence which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO:3. The proteins are human **CLCA1**, **CLCA2** and **CLCA4** proteins. Polyclonal and monoclonal antibodies, and **antisense** DNA or oligonucleotides are useful as diagnostic or therapeutic agent for bronchial asthma and COPD, as well as for drug screening.

L10 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AB Use of cells expressing mouse gob-5 or human **CLCA** gene in screening therapeutic agents for respiratory diseases such as bronchial asthma or chronic obstructive pulmonary disease or rhinitis, is provided. Here, the authors show that gob-5, a member of the calcium-activated chloride channel family, is a key mol. in the induction of murine asthma. Intratracheal administration of adenovirus-expressing **antisense** gob-5 RNA into AHR-model mice efficiently suppressed the asthma phenotype, including AHR and mucus overprodn. In contrast, overexpression of gob-5 in airway epithelia by using an adenoviral vector exacerbated the asthma phenotype. Introduction of either gob-5 or **hCLCA1**, the human counterpart of gob-5, into the human mucoepidermoid cell line NCI-H292 induced mucus prodn. as well as MUC5AC expression. Their results indicated that gob-5 may play a crit. role in murine asthma, and its human counterpart **hCLCA1** is therefore a potential target for asthma therapy.

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AB Described herein are methods that can be used for diagnosis and prognosis of colorectal cancer. The invention provides 1747 genes that are up-regulated in colorectal tumors from a variety of stages of the disease. The genes that are up-regulated in the tumors are expressed at a limited amt. or not at all in the body map consisting of 28 tissue types. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate colorectal cancer. Addnl., methods and mol. targets (genes and their products) for therapeutic intervention in colorectal and other cancers are described.

L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AB Use of inhibitors of human calcium-activated chloride channels **CLCA1**, **CLCA2**, and **CLCA4** and mouse homolog gob-5 as diagnostic agent or therapeutic agent, is disclosed. Use in drug screening and reagent kit are also claimed. **Antisense** nucleic acid or antibodies are used as diagnostic agent or therapeutic agent for rhinitis. Expression of **CLCA** genes was found to be significantly elevated in rhinitis patients.

L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AB Nucleic acid mols., including antisense and enzymic nucleic acid mols., such as hammerhead ribozymes, DNazymes, and GeneBlocks, which modulate the expression of calcium-activated chloride channels (CLCA1, CLCA2, CLCA3, and CLCA4) are provided. A target discovery target validation approach was used for finding genes that are involved in chronic mucous hypersecretion. The reporter system consists of a plasmid construct, termed pMUC5AC-EGFP, bearing a gene coding for green fluorescent protein (GFP). The promoter region of the GFP gene is replaced by a portion of the mucin 5AC promoter sufficient to direct efficient transcription of the GFP gene; the plasmid also contains the neomycin drug resistance gene. The cell line selected as host for these studies, NCI-H292 (ATCC CRL-1848), is derived from a human lung mucoepidermoid carcinoma. A ribozyme library with two randomized regions comprising six-nucleotide binding "arms" is used to enrich cells for non-responders to mucin induction and a bioinformatics approach used to identify human CLCA1 as a regulator of MUC5AC expression. Antisense, hammerhead, DNzyme, NCH, amberzyme, zinzyme, and G-Cleaver ribosome binding/cleavage sites in CLCA1 were identified. The nucleic acid mols. are individually analyzed by computer folding to assess whether the sequences fold into the appropriate secondary structure and to anneal to various sites in the RNA target. Those nucleic acid mols. with unfavorable intramol. interactions such as between the binding arms and the catalytic core are eliminated from consideration. Varying binding arm lengths can be chosen to optimize activity.

L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AB An antisense DNA to airway disease-assocd. genes gob-5 and hCLCA1; drugs contg. this antisense DNA; an antibody against the gene products; and diagnostic reagents contg. the antibody; are disclosed. A method and reagent kits for screening a compd. inhibiting the activity of the disease-assocd. gene product for prevention and treatment for bronchial asthma and chronic obstructive pulmonary disease, are claimed. Protein. Airway hyperresponsiveness (AHR), goblet cell metaplasia, and mucus overprodn. are important features of bronchial asthma. To elucidate the mol. mechanisms behind these pulmonary pathologies, we examd. for genes preferentially expressed in the lungs of a murine model of allergic asthma by using suppression subtractive hybridization (SSH). We identified a gene called gob-5 that had a selective expression pattern in the airway epithelium with AHR. Here, we show that gob-5, a member of the calcium-activated chloride channel family, is a key mol. in the induction of murine asthma. Intratracheal administration of adenovirus-expressing antisense gob-5 RNA into AHR-model mice efficiently suppressed the asthma phenotype, including AHR and mucus overprodn. In contrast, overexpression of gob-5 in airway epithelia by using an adenoviral vector exacerbated the asthma phenotype. Introduction of either gob-5 or hCLCA1, the human counterpart of gob-5, into the human mucoepidermoid cell line NCI-H292 induced mucus prodn. as well as MUC5AC expression. Our results indicated that gob-5 may play a crit. role in murine asthma, and its human counterpart hCLCA1 is therefore a potential target for asthma therapy.

L10 ANSWER 7 OF 7 MEDLINE on STN

DUPLICATE 1

AB Airway hyperresponsiveness (AHR), goblet cell metaplasia, and mucus overproduction are important features of bronchial asthma. To elucidate the molecular mechanisms behind these pulmonary pathologies, we examined for genes preferentially expressed in the lungs of a murine model of allergic asthma by using suppression subtractive hybridization (SSH). We identified a gene called gob-5 that had a selective expression pattern in the airway epithelium with AHR. Here, we show that gob-5, a member of the calcium-activated chloride channel family, is a key molecule in the induction of murine asthma. Intratracheal administration of adenovirus-expressing antisense gob-5 RNA into AHR-model mice efficiently suppressed the asthma phenotype, including AHR and mucus

overproduction. In contrast, overexpression of gob-5 in airway epithelia by using an adenoviral vector exacerbated the asthma phenotype. Introduction of either gob-5 or hCLCA1, the human counterpart of gob-5, into the human mucoepidermoid cell line NCI-H292 induced mucus production as well as MUC5AC expression. Our results indicated that gob-5 may play a critical role in murine asthma, and its human counterpart hCLCA1 is therefore a potential target for asthma therapy.

=> d 1-7

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:434841 CAPLUS

DN 139:21032

TI Antibodies and antisense DNA specific to CLCA1, CLCA2 and CLCA4 proteins for drug screening and diagnosis and treatment of chronic obstructive pulmonary disease

IN Nakanishi, Atsushi; Morita, Shigeru

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003046553	A1	20030605	WO 2002-JP12421	20021128 ✓
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
JP 2003227822	A2	20030815	JP 2002-345422	20021128
PRAI JP 2001-364715	A	20011129		
RE.CNT 7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L10 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:417869 CAPLUS

DN 139:3212

TI Mouse gob-5 and human CLCA chloride channel expressing cells for screening asthma and chronic obstructive pulmonary disease drugs

IN Nakanishi, Atsushi; Morita, Shigeru

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003044182	A1	20030530	WO 2002-JP12051	20021119 ✓
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,			

RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG

JP 2003219867 A2 20030805 JP 2002-334938 20021119  
PRAI JP 2001-354262 A 20011120  
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2003:319333 CAPLUS  
DN 138:319167  
TI Differentially expressed genes for diagnosis of colorectal cancer and  
compositions and methods of screening for colorectal cancer modulators  
IN Gish, Kurt C.; Mack, David H.; Wilson, Keith E.  
PA USA  
SO U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 663,733,  
abandoned.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003077568 ✓	A1	20030424	US 2001-930020	20010814
	WO 2002021996	A2	20020321	WO 2001-US28716	20010914
	WO 2002021996	A3	20030206		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1317669	A2	20030611	EP 2001-970958	20010914
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-663733	B2	20000915		
	US 2001-930020	A	20010814		
	WO 2001-US28716	W	20010914		

L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2003:596564 CAPLUS  
DN 139:160825  
TI Human calcium-dependent chloride channels CLCA and mouse gob-5 inhibitors  
for use in rhinitis therapy, diagnosis, and drug screening  
IN Nakanishi, Atsushi; Morita, Shigeru  
PA Takeda Chemical Industries, Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 35 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003221344	A2	20030805	JP 2002-207635	20020717
PRAI	JP 2001-218078	A	20010718		
	JP 2001-354284	A	20011120		

L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:122738 CAPLUS  
 DN 136:194272  
 TI Ribozymes and antisense oligonucleotides for the inhibition of gene  
 expression by calcium-activated chloride channel-1 gene CLCA-1  
 IN Thompson, James; McSwiggen, James; McKenzie, Timothy; Ayers, David;  
 Szymkowski, David E.; Grupe, Andrew  
 PA Ribozyme Pharmaceuticals, Incorporated, USA; Syntex (U.S.A.) LLC  
 SO PCT Int. Appl., 152 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002011674	A2	20020214	WO 2001-US24970	20010809
	WO 2002011674	A3	20030925		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003064946	A1	20030403	US 2001-927046	20010809
PRAI	US 2000-224383P	P	20000809		

L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2001:397048 CAPLUS  
 DN 135:15058  
 TI Mouse gob-5 and human hCLCA1 gene antisense DNA for  
 asthma and chronic obstructive pulmonary disease therapy  
 IN Nakanishi, Atsushi; Morita, Shigeru  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 104 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001038530	A1	20010531	WO 2000-JP8232	20001122
	W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001015484	A5	20010604	AU 2001-15484	20001122
	JP 2002010791	A2	20020115	JP 2000-356049	20001122
	EP 1234878	A1	20020828	EP 2000-977857	20001122
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	JP 1999-333479	A	19991124		
	JP 2000-127589	A	20000427		
	WO 2000-JP8232	W	20001122		
RE.CNT	10	THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L10 ANSWER 7 OF 7 MEDLINE on STN DUPLICATE 1  
 AN 2001231619 MEDLINE

DN 21221098 PubMed ID: 11296262  
 TI Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma.  
 AU Nakanishi A; Morita S; Iwashita H; Sagiya Y; Ashida Y; Shirafuji H; Fujisawa Y; Nishimura O; Fujino M  
 CS Discovery Research Laboratories II, Pharmaceutical Discovery Research Division, Takeda Chemical Industries Ltd., 10 Wadai, Tsukuba, Ibaraki 300-4293, Japan.. Nakanishi\_Atsushi@takeda.co.jp  
 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2001 Apr 24) 98 (9) 5175-80.  
 Journal code: 7505876. ISSN: 0027-8424.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200105  
 ED Entered STN: 20010529  
 Last Updated on STN: 20030105  
 Entered Medline: 20010521

=> d his

(FILE 'HOME' ENTERED AT 13:03:26 ON 30 DEC 2003)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOTECHNO, SCISEARCH, BIOSIS' ENTERED AT 13:04:08 ON 30 DEC 2003

L1 104 S CLCA1  
 L2 75 S HCLCA1  
 L3 14 S CLCA-1  
 L4 10 S HCLCA-1  
 L5 175 S L1 OR L2 OR L3 OR L4  
 L6 1 S L5 AND RIBOZYME  
 L7 12 S L5 AND ANTISENSE  
 L8 0 S L5 AND SIRNA  
 L9 0 S L5 AND RNAI  
 L10 7 DUP REM L7 (5 DUPLICATES REMOVED)

=> d l6

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2002:122738 CAPLUS  
 DN 136:194272  
 TI Ribozymes and antisense oligonucleotides for the inhibition of gene expression by calcium-activated chloride channel-1 gene CLCA-1  
 IN Thompson, James; McSwiggen, James; McKenzie, Timothy; Ayers, David; Szymkowski, David E.; Grupe, Andrew  
 PA Ribozyme Pharmaceuticals, Incorporated, USA; Syntex (U.S.A.) LLC  
 SO PCT Int. Appl., 152 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002011674	A2	20020214	WO 2001-US24970	20010809
	WO 2002011674	A3	20030925		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,			



DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 2003064946 A1 20030403 US 2001-927046 20010809  
 PRAI US 2000-224383P P 20000809

=> s chloride channel calcium activated  
 L11 108 CHLORIDE CHANNEL CALCIUM ACTIVATED

=> s l11 not l5  
 L12 95 L11 NOT L5

=> s l5 and antisense  
 L13 12 L5 AND ANTISENSE

=> s l12 and antisense  
 L14 4 L12 AND ANTISENSE

=> dup rem l14  
 PROCESSING COMPLETED FOR L14  
 L15 4 DUP REM L14 (0 DUPLICATES REMOVED)

=> s l12 and ribozyme  
 L16 0 L12 AND RIBOZYME

=> s l12 and ribozymes  
 L17 0 L12 AND RIBOZYMES

=> d 1-4 l14

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:590937 CAPLUS

DN 139:143886

TI Method for identifying compounds to treat urological disorders by  
 measuring their effect on disease-related genes and proteins, and use of  
 the identified compounds in treatment

IN Silos-Santiago, Inmaculada; Karicheti, Venkateswarlu

PA Millennium Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 242 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003061573	A2	20030731	WO 2003-US1450	20030116
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003148394	A1	20030807	US 2003-345680	20030116
PRAI	US 2002-349511P	P	20020118		
	US 2002-360500P	P	20020228		
	US 2002-365041P	P	20020315		
	US 2002-374063P	P	20020419		
	US 2002-403468P	P	20020814		
	US 2002-414262P	P	20020927		

US 2002-419986P P 20021021  
 US 2002-423809P P 20021105  
 US 2002-429797P P 20021126

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2003:42530 CAPLUS  
 DN 138:102039  
 TI Human calcium-dependent chloride channel CLCA4 and its use in drug  
 screening and respiratory disease diagnosis and therapy  
 IN Nakanishi, Atsushi; Morita, Shigeru  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 84 pp.  
 CODEN: P1XXD2

DT Patent  
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003005024	A1	20030116	WO 2002-JP6730	20020703
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	JP 2003125788	A2	20030507	JP 2002-194957	20020703
PRAI	JP 2001-203036	A	20010704		
RE.CNT	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2001:888573 CAPLUS  
 DN 136:132060  
 TI The voltage-dependent Cl<sup>-</sup> channel ClC-5 and plasma membrane Cl<sup>-</sup> conductances of mouse renal collecting duct cells (mIMCD-3)  
 AU Sayer, J. A.; Stewart, G. S.; Boese, S. H.; Gray, M. A.; Pearce, S. H. S.; Goodship, T. H. J.; Simmons, N. L.  
 CS Department of Physiological Sciences, Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK  
 SO Journal of Physiology (Cambridge, United Kingdom) (2001), 536(3), 769-783  
 CODEN: JPHYA7; ISSN: 0022-3751  
 PB Cambridge University Press  
 DT Journal  
 LA English

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
 AN 2000:226281 BIOSIS  
 DN PREV200000226281  
 TI Modulation of the Ca<sup>2+</sup>-activated Cl<sup>-</sup> channel by 14-3-3epsilon.  
 AU Chan, H. C.; Wu, W. L.; So, S. C.; Chung, Y. W.; Tsang, L. L.; Wang, X. F.; Yan, Y. C.; Luk, S. C. W.; Siu, S. S.; Tsui, S. K. W.; Fung, K. P.; Lee, C. Y.; Wayne, M. M. Y. [Reprint author]  
 CS Hong Kong Bioinformatics Centre, Faculty of Medicine, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China  
 SO Biochemical and Biophysical Research Communications, (April 13, 2000) Vol. 270, No. 2, pp. 581-587. print.  
 CODEN: BBRCA9. ISSN: 0006-291X.  
 DT Article

LA English  
ED Entered STN: 7 Jun 2000  
Last Updated on STN: 5 Jan 2002

=> d ab 1-4 114

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

AB The present invention relates to methods for the diagnosis and treatment of a urol. disorder or urol. disorders. Specifically, the present invention identifies the differential expression of 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 and 6351 genes in tissues relating to urol. disorders, relative to their expression in normal, or non-urol. disorders, and/or in response to manipulations relevant to a urol. disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urol. disorders, and for the identification of subjects exhibiting a predisposition to such conditions. glucose. The invention also provides methods for identifying a compd. capable of modulating a urol. disorder or urol. disorders. The present invention also provides methods for the identification and therapeutic use of compds. as treatments of urol. disorders.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

AB Use of calcium-dependent chloride channel CLCA4 for drug screening is provided. Use of **antisense** nucleic acids and neutralizing antibodies to CLCA4 as diagnostic agent or therapeutic agent for respiratory diseases, bronchial asthma and chronic obstructive pulmonary disease (COPD), in particular, is claimed. Expression of CLCA4 gene was found to be significantly elevated in COPD patients. Recombinant expression of hCLCA4 in CHO cells resulted in the appearance of a prominent calcium-activated chloride current. These results showed CLCA4 functions as calcium-activated chloride channels.

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

AB We have tested the hypothesis that the voltage-dependent Cl<sup>-</sup> channel, ClC-5 functions as a plasma membrane Cl<sup>-</sup> conductance in renal inner medullary collecting duct cells. Full-length mouse kidney ClC-5 (mClC-5) was cloned and transiently expressed in CHO-K1 cells. Fast whole-cell patch-clamp recordings confirmed that mClC-5 expression produces a voltage-dependent, strongly outwardly rectifying Cl<sup>-</sup> conductance that was unaffected by external DIDS. Slow whole-cell recordings, using nystatin-perforated patches from transfected CHO-K1 cells, also produced voltage-dependent Cl<sup>-</sup> currents consistent with ClC-5 expression. However, under this recording configuration an endogenous DIDS-sensitive Ca<sup>2+</sup>-activated Cl<sup>-</sup> conductance was also evident, which appeared to be activated by green fluorescent protein (GFP) transfection. A mClC-5-GFP fusion protein was transiently expressed in CHO-K1 cells; confocal laser scanning microscopy (CLSM) showed localization at the plasma membrane, consistent with patch-clamp expts. Endogenous expression of mClC-5 was demonstrated in mouse renal collecting duct cells (mIMCD-3) by RT-PCR and by immunocytochem. Using slow whole-cell current recordings, mIMCD-3 cells displayed three biophys. distinct Cl<sup>-</sup>-selective currents, which were all inhibited by DIDS. However, no cells exhibited whole-cell currents that had mClC-5 characteristics. Transient transfection of mIMCD-3 cells with **antisense** mClC-5 had no effect on the endogenous Cl<sup>-</sup> conductances. Transient transfection with sense mClC-5 failed to induce the Cl<sup>-</sup> conductance seen in CHO-K1 cells but stimulated levels of the endogenous Ca<sup>2+</sup>-activated Cl<sup>-</sup> conductance 24 h post-transfection. Confocal laser scanning microscopy of mIMCD-3 cells transfected with mClC-5-GFP showed that the protein was absent from the plasma membrane and was instead localized to acidic endosomal compartments. These data discount a major role for ClC-5 as a plasma membrane Cl<sup>-</sup> conductance in mIMCD-3 cells but suggest a role in endosomal function.

L14 ANSWER 4 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
AB We have previously reported an association of 14-3-3epsilon isoform with calmodulin. Using the voltage-clamp technique, the present study investigated the potential role of 14-3-3 in modulating the Ca<sup>2+</sup>-activated Cl<sup>-</sup> channel (CaCC) endogenously expressed in *Xenopus* oocytes. Injection of 14-3-3epsilon **antisense** oligodeoxy-nucleotides resulted in potentiation of the ionomycin-induced Cl<sup>-</sup> current, while 14-3-3 peptide and calmodulin inhibitor, W13, suppressed the **antisense**-potentiated current. The data suggest that 14-3-3epsilon plays an inhibitory role in modulating the CaCC by interacting with the calmodulin-dependent pathway. The potential role of 14-3-3epsilon in other tissues and its therapeutic potential for cystic fibrosis are discussed.